Taken together, metformin reduces the motility of vascular smooth muscle cells through the activation of the AMPK–Pdlim5 pathway, which contributes to the protective effects of metformin against diabetes-accelerated atherosclerosis and is beneficial for the therapy of metabolic syndrome. Here, PRKAA1 is linked to diabetes mellitus.